CARsgen Therapeutics Holdings Limited (HKG:2171)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
15.90
+1.98 (14.22%)
At close: Mar 10, 2026
-1.00%
Market Cap 7.74B
Revenue (ttm) 139.84M
Net Income (ttm) -108.90M
Shares Out 555.80M
EPS (ttm) -0.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,954,030
Average Volume 4,327,404
Open 14.44
Previous Close 13.92
Day's Range 14.00 - 16.19
52-Week Range 9.90 - 25.60
Beta 0.40
RSI 56.53
Earnings Date Mar 6, 2026

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 371
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

In 2025, HKG:2171's revenue was 125.66 million, an increase of 218.74% compared to the previous year's 39.43 million. Losses were -97.86 million, -87.74% less than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.